DERENZINI, ENRICO
 Distribuzione geografica
Continente #
NA - Nord America 3.172
EU - Europa 2.347
AS - Asia 1.008
AF - Africa 138
SA - Sud America 14
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 2
Totale 6.686
Nazione #
US - Stati Uniti d'America 3.159
GB - Regno Unito 675
VN - Vietnam 489
SE - Svezia 481
CN - Cina 338
DE - Germania 301
IT - Italia 238
IN - India 121
IE - Irlanda 114
UA - Ucraina 88
FR - Francia 87
RU - Federazione Russa 81
CH - Svizzera 79
EE - Estonia 61
ZA - Sudafrica 57
TG - Togo 47
BE - Belgio 34
FI - Finlandia 29
BG - Bulgaria 24
HR - Croazia 19
NG - Nigeria 16
CI - Costa d'Avorio 14
CA - Canada 13
IR - Iran 13
JO - Giordania 10
BR - Brasile 9
GR - Grecia 8
JP - Giappone 8
PL - Polonia 8
LB - Libano 7
CZ - Repubblica Ceca 5
ES - Italia 5
HK - Hong Kong 4
NL - Olanda 4
SC - Seychelles 4
AU - Australia 3
CL - Cile 3
TR - Turchia 3
UZ - Uzbekistan 3
BD - Bangladesh 2
HU - Ungheria 2
MY - Malesia 2
NZ - Nuova Zelanda 2
PE - Perù 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
AT - Austria 1
BY - Bielorussia 1
EU - Europa 1
ID - Indonesia 1
KR - Corea 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
PH - Filippine 1
PK - Pakistan 1
RO - Romania 1
RS - Serbia 1
TM - Turkmenistan 1
Totale 6.686
Città #
Southend 605
Fairfield 448
Chandler 344
Dong Ket 310
Ashburn 283
Woodbridge 228
Houston 221
Wilmington 203
Seattle 190
Ann Arbor 173
Princeton 141
Cambridge 133
Dublin 114
Bern 76
Nanjing 67
Westminster 63
Padova 60
Lomé 47
Jacksonville 45
Berlin 42
New York 41
Jinan 38
Bologna 36
Brussels 34
Beijing 32
San Diego 32
Changsha 31
Boardman 30
Helsinki 29
Florence 28
Saint Petersburg 27
Shenyang 27
Hebei 26
Bremen 25
Sofia 24
Turin 21
Redwood City 19
Jiaxing 17
Medford 17
Abeokuta 16
Dearborn 15
Norwalk 15
Abidjan 14
Mülheim 13
Nanchang 13
Redmond 13
Toronto 13
Ningbo 12
Taizhou 11
Amman 10
Haikou 9
Falls Church 8
Hangzhou 8
Mountain View 8
Olalla 8
Lanzhou 7
London 7
São Paulo 7
Tianjin 7
Zhengzhou 7
Monmouth Junction 6
Pune 6
Rijeka 6
San Francisco 6
Warsaw 6
Andover 5
Des Moines 5
Falconara Marittima 5
Los Angeles 5
Milan 5
Taiyuan 5
Wayne 5
Zanjan 5
Fremont 4
Hanover 4
Henderson 4
Kunming 4
Mahé 4
Phoenix 4
Hefei 3
Kuban 3
Leawood 3
Paris 3
Reggio Emilia 3
San Venanzo 3
Tokyo 3
Ardabil 2
Athens 2
Auckland 2
Brno 2
Catania 2
Ceska 2
Fiumicino 2
Frankfurt Am Main 2
Giulianova 2
Greenock 2
Groningen 2
Guangzhou 2
Kish 2
Las Vegas 2
Totale 4.691
Nome #
A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by 90Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma. 190
A phase I study of continuous hepatic arterial infusion of Irinotecan in patients with locally advanced hepatocellular carcinoma. 185
Adjuvant systemic chemotherapy after putative curative resection of colorectal liver and lung metastases. 181
Allotransplant in relapsed or refractory aggressive T-cell lymphomas: retrospective monocentric analysis of 14 patients 171
A phase 2 trial of fludarabine and mitoxantrone chemoterapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma 171
Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: evaluation of the long-term outcome. 144
Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. 143
Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study 141
Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials. 140
Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma. 140
High efficacy of the MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis, a 20 year experience 139
Association of essential thrombocythemia and non-Hodgkin lymphoma: a single-centre experience 135
Dissection of DLBCL Microenvironment Provides a Gene Expression-Based Predictor of Survival Applicable to Formalin-Fixed Paraffin-Embedded Tissue 133
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 133
An isolated penile mass in a young adult turned out to be a primary marginal zone lymphoma of the penis. A case report and a review of literature. 128
Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: A new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients 127
Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients. 126
Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma 126
RALE051: a novel established cell line of sporadic Burkitt lymphoma 124
Role of [18F]Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of Lymphoma 124
Extramedullary myeloid tumour of the stomach and duodenum presenting without acute myeloblastic leukemia: a diagnostic and therapeutic challenge. 121
Collection of Hematopoietic Stem Cells after Previous Radioimmunotherapy is Feasible and Does Not Impair Engraftment after Autologous Stem Cell Transplantation in Follicular Lymphoma. 120
The Novel Small Molecule Chk1/Chk2 Inhibitor PF-0477736 (Pfizer) Is Highly Active As Single Agent in Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) 115
Treatment of colorectal cancer liver metastases 113
Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. 112
In Vitro and in Vivo Single-Agent Efficacy of Checkpoint Kinase 1 (Chk1) and 2 (Chk2) Inhibitor PF-0477736 (Pfizer) in B- and T-Acute Lymphoblastic Leukemia (ALL) 112
Successful combination treatment of clofarabine, cytarabine, and gemtuzumab-ozogamicin in adult refractory B-acute lymphoblastic leukemia. 111
Long-term efficacy and toxicity results of the FLUMIZ trial (fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in untreated follicular lymphoma). 111
Bendamustine: role and evidence in lymphoma therapy, an overview. 111
Non-hodgkin lymphomas presenting as soft tissue masses: a single center experience and meta-analysis of the published series. 110
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 108
Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma. 105
Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia 105
Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specified. 105
Complete response of relapsed systemic and cutaneous anaplastic large cell lymphoma using brentuximab vedotin: 2 case reports. 105
Inhibition of DNA repair by the small molecule Chk1/Chk2 inhibitor PF-0477736 (Pfizer) in B-acute lymphoblastic leukemia (ALL) 104
Bendamustine efficacy in Hodgkin lymphoma patients relapsed/refractory to brentuximab vedotin. 103
Extranodal marginal zone B-cell lymphoma of the lung: experience with fludarabine and mitoxantrone-containing regimens. 102
Prognostic value of interim positron emission tomography in patients with peripheral T-cell lymphoma. 98
Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomicin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 0-1) diffuse large B-cell lymphoma. Leuk Lymphoma. 97
Clinical safety and efficacy of adjuvant chemotherapy in radically resected cholangiocarcinoma patients. 96
The Small Molecule CHK1/CHK2 Inhibitor PF-0477736 (Pfizer) Demonstrates Single Agent Activity and Synergizes with Chemotherapy in Diffuse Large B-Cell Lymphoma 93
The Inhibition of Checkpoint Kinase 1 As a Promising Strategy to Increase the Effectiveness of Different Treatments in Acute Lymphoblastic Leukemia 93
The synergistic efficacy of Chk1/Chk2 inhibitors and doxorubicin in the treatment of acute lymphoblastic leukemia 93
FDG-PET in the assessment of patients with follicular lymphoma treated by ibritumomab tiuxetan Y 90: multicentric study. 92
Severe peripheral motor neuropathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin. 92
Treatment of hepatic metastases from colorectal cancer: many doubts, some certainties. 91
Long-term efficacy of the combination of lenalidomide and rituximab in elderly relapsed/refractory diffuse large B-cell lymphoma patients. 90
Impact of adjuvant chemotherapy on time to relapse in cholangiocarcinoma. 89
Hairy cell leukemia: evaluation of the long-term outcome in 121 patients. 83
Postchemotherapy PET evaluation correlates with patient outcome in paediatric Hodgkin's disease. 80
GEMOX AS FIRST-LINE CHEMOTHERAPY IN ADVANCED PANCREATIC CANCER (APC): A MONOISTITUTIONAL EXPERIENCE. 75
null 75
The small molecule CHK1/CHK2 inhibitor PF-0477736 (Pfizer) demonstrates single agent activity in diffuse large B-cell lymphoma 72
SINGLE-AGENT INHIBITION OF CHECKPOINT KINASE 1 (CHK1) AND 2 (CHK2) BY PF-0477736 (PFIZER) AS A NEW PROMISING THERAPY IN B-ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) 71
Sequential therapy with alternating short courses of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) and R-FM (rituximab, fludarabine, mitoxantrone) followed by autologous stem cell transplantation results in long term remission in advanced follicular lymphoma. 71
Systemic adjuvant chemotherapy after resection of colorectal cancer metastases 71
IMPACT OF MULTIDISCIPLINARY APPROACH ON SURVIVAL OF PATIENTS WITH KLATSKIN TUMOR 70
Phase I/II trial of continuous hepatic arterial infusion (HAI) of Irinotecan in patients with hepatocellular carcinoma (HCC). Preliminary results 57
The tratment of liver metastases from colorectal cancer: questions more than answers? 51
Liver metastases from colorectal cancer 47
METRONOMIC CAPECITABINE IN ADVANCED PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC): PRELIMINARY RESULTS. 46
Phase I/II trial of continuous hepatic arterial infusion (HAI) of irinotecan in patients with hepatocellular carcinoma (HCC). 37
Therapeutic implications of intratumor heterogeneity for TP53 mutational status in Burkitt lymphoma 22
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study 12
Totale 6.838
Categoria #
all - tutte 14.163
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14.163


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019233 0 0 0 0 0 0 0 0 44 73 23 93
2019/20201.924 262 62 16 111 193 209 232 239 283 117 91 109
2020/20211.088 177 62 33 28 24 66 7 45 93 34 52 467
2021/20221.385 196 53 104 144 108 71 45 71 48 89 245 211
2022/20231.527 197 200 83 189 96 120 32 85 217 49 122 137
2023/2024311 30 65 15 50 27 91 19 14 0 0 0 0
Totale 6.838